Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996165642> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2996165642 endingPage "S477" @default.
- W2996165642 startingPage "S477" @default.
- W2996165642 abstract "Nivolumab in combination with ipilimumab (NIVO+IPI) is the first immuno-oncology combination to demonstrate significant, long-term overall survival (OS) benefit in previously untreated patients with intermediate- to poor-risk advanced renal cell carcinoma (1L RCC) compared with standard of care (sunitinib). The objective of this study was to assess the cost-effectiveness of NIVO+IPI compared with sunitinib in 1L RCC from the French all payers perspective. A three-state partitioned survival model (progression-free disease, progressed disease and death) was developed with a one-week cycle length and lifetime time horizon. The model used patient characteristics, progression-free survival, OS, safety data and utilities (EQ-5D-3L) from the CheckMate-214 trial (NCT02231749). French costs for drug acquisition, drug administration, monitoring, terminal care, travel and adverse events were sourced from published prices. Treatment-specific utilities were calculated using the French value set. Costs and outcomes were discounted by 4.0% annually. Univariate deterministic and multivariate probabilistic sensitivity analyses (DSA, PSA) assessed robustness of the results. Outcomes of interest were total costs, quality-adjusted life-years (QALYs), life years (LYs), the incremental cost-utility ratio (ICUR), and the incremental cost-effectiveness ratio (ICER). NIVO+IPI was associated with higher total QALYs and LYs (3.53 and 4.95) versus sunitinib (2.71 and 3.87) and increased total cost (€160,751 versus €86,596), all respectively. This resulted in an ICUR of €89,793/QALY gained and an ICER of €68,626/LY gained versus sunitinib. Based on the DSA, key model drivers were drug acquisition costs, QALY discount rate, and variation of OS function parameters (95% confidence interval). The PSA confirmed robustness of the model results, with NIVO+IPI having a 62% probability of being cost-effective at a willingness-to-pay (WTP) threshold of €100,000/QALY. Driven by an increased and sustained OS benefit, NIVO+IPI would be a cost-effective treatment when compared with sunitinib for 1L RCC patients in France at a WTP threshold of €100,000/QALY." @default.
- W2996165642 created "2019-12-26" @default.
- W2996165642 creator A5007130219 @default.
- W2996165642 creator A5020353650 @default.
- W2996165642 creator A5029301001 @default.
- W2996165642 creator A5035035805 @default.
- W2996165642 creator A5036950727 @default.
- W2996165642 creator A5050003681 @default.
- W2996165642 creator A5067941899 @default.
- W2996165642 creator A5080756848 @default.
- W2996165642 creator A5081092375 @default.
- W2996165642 date "2019-11-01" @default.
- W2996165642 modified "2023-09-27" @default.
- W2996165642 title "PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE" @default.
- W2996165642 doi "https://doi.org/10.1016/j.jval.2019.09.410" @default.
- W2996165642 hasPublicationYear "2019" @default.
- W2996165642 type Work @default.
- W2996165642 sameAs 2996165642 @default.
- W2996165642 citedByCount "1" @default.
- W2996165642 countsByYear W29961656422023 @default.
- W2996165642 crossrefType "journal-article" @default.
- W2996165642 hasAuthorship W2996165642A5007130219 @default.
- W2996165642 hasAuthorship W2996165642A5020353650 @default.
- W2996165642 hasAuthorship W2996165642A5029301001 @default.
- W2996165642 hasAuthorship W2996165642A5035035805 @default.
- W2996165642 hasAuthorship W2996165642A5036950727 @default.
- W2996165642 hasAuthorship W2996165642A5050003681 @default.
- W2996165642 hasAuthorship W2996165642A5067941899 @default.
- W2996165642 hasAuthorship W2996165642A5080756848 @default.
- W2996165642 hasAuthorship W2996165642A5081092375 @default.
- W2996165642 hasBestOaLocation W29961656421 @default.
- W2996165642 hasConcept C112930515 @default.
- W2996165642 hasConcept C121608353 @default.
- W2996165642 hasConcept C126322002 @default.
- W2996165642 hasConcept C143998085 @default.
- W2996165642 hasConcept C2777472916 @default.
- W2996165642 hasConcept C2777701055 @default.
- W2996165642 hasConcept C2779490328 @default.
- W2996165642 hasConcept C2780030458 @default.
- W2996165642 hasConcept C2781433595 @default.
- W2996165642 hasConcept C3019080777 @default.
- W2996165642 hasConcept C515549039 @default.
- W2996165642 hasConcept C71924100 @default.
- W2996165642 hasConceptScore W2996165642C112930515 @default.
- W2996165642 hasConceptScore W2996165642C121608353 @default.
- W2996165642 hasConceptScore W2996165642C126322002 @default.
- W2996165642 hasConceptScore W2996165642C143998085 @default.
- W2996165642 hasConceptScore W2996165642C2777472916 @default.
- W2996165642 hasConceptScore W2996165642C2777701055 @default.
- W2996165642 hasConceptScore W2996165642C2779490328 @default.
- W2996165642 hasConceptScore W2996165642C2780030458 @default.
- W2996165642 hasConceptScore W2996165642C2781433595 @default.
- W2996165642 hasConceptScore W2996165642C3019080777 @default.
- W2996165642 hasConceptScore W2996165642C515549039 @default.
- W2996165642 hasConceptScore W2996165642C71924100 @default.
- W2996165642 hasLocation W29961656421 @default.
- W2996165642 hasOpenAccess W2996165642 @default.
- W2996165642 hasPrimaryLocation W29961656421 @default.
- W2996165642 hasRelatedWork W2792937256 @default.
- W2996165642 hasRelatedWork W2794528692 @default.
- W2996165642 hasRelatedWork W2900401531 @default.
- W2996165642 hasRelatedWork W2966932534 @default.
- W2996165642 hasRelatedWork W2981065291 @default.
- W2996165642 hasRelatedWork W2995949655 @default.
- W2996165642 hasRelatedWork W3098031000 @default.
- W2996165642 hasRelatedWork W3152520552 @default.
- W2996165642 hasRelatedWork W4200503638 @default.
- W2996165642 hasRelatedWork W4362587156 @default.
- W2996165642 hasVolume "22" @default.
- W2996165642 isParatext "false" @default.
- W2996165642 isRetracted "false" @default.
- W2996165642 magId "2996165642" @default.
- W2996165642 workType "article" @default.